BridgeBio's Calcilytix Sees POC For Encaleret And Options To Discuss With FDA

Company Presents Early Phase II Data At ENDO

 
• By Alaric DeArment

Calcilytix chief medical officer Jonathan Fox talked to Scrip about the development plans for encaleret for the rare form of hypoparathyroidism.

Yellow road sign with a blue sky and white clouds: clinical trial
BridgeBio presented Phase IIb proof-of-concept data and hopes to meet with the FDA later in 2021 or early 2022. • Source: Shutterstock

More from R&D

More from Scrip